Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Cash & Current Investments (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Cash & Current Investments for 5 consecutive years, with $75.7 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cash & Current Investments fell 38.57% year-over-year to $75.7 million, compared with a TTM value of $75.7 million through Dec 2024, down 38.57%, and an annual FY2024 reading of $75.7 million, down 38.57% over the prior year.
  • Cash & Current Investments was $75.7 million for Q4 2024 at Treace Medical Concepts, down from $82.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $123.2 million in Q4 2023 and bottomed at $10.3 million in Q2 2020.
  • Average Cash & Current Investments over 5 years is $67.4 million, with a median of $82.0 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments skyrocketed 1060.81% in 2021, then crashed 88.15% in 2023.
  • Year by year, Cash & Current Investments stood at $18.1 million in 2020, then surged by 485.39% to $105.8 million in 2021, then fell by 23.23% to $81.3 million in 2022, then soared by 51.62% to $123.2 million in 2023, then plummeted by 38.57% to $75.7 million in 2024.
  • Business Quant data shows Cash & Current Investments for TMCI at $75.7 million in Q4 2024, $82.8 million in Q3 2024, and $18.2 million in Q2 2024.